Scientists are developing a new class of drug, oveporexton, that targets the brain's orexin system, offering a potential breakthrough for narcolepsy and other neurological conditions. This twice-daily pill is designed to boost levels of orexin, a peptide crucial for regulating wakefulness and sleep.
Oveporexton has received U.S. Food and Drug Administration approval for narcolepsy and is currently under review by the UK's National Institute for Health and Care Excellence for potential NHS treatment, with a decision expected by April 2027. The drug targets type-1 narcolepsy, the most common form, believed to arise when the immune system mistakenly attacks the brain cells responsible for producing orexin. Oveporexton stimulates receptors that increase orexin production, thereby helping to control sleep and wakefulness.
Narcolepsy affects approximately 30,000 people in the UK, often emerging in childhood or early adulthood. Sufferers can experience sudden, uncontrollable sleep episodes, sometimes accompanied by cataplexy—a brief loss of muscle control triggered by strong emotions. Current treatments, such as modafinil and sodium oxybate, address symptoms but can have significant side effects. Oveporexton is considered a significant advancement as it targets the underlying cause of the condition. In clinical trials, patients taking oveporexton showed improved daytime alertness and an average 80% reduction in cataplexy rates, with mostly mild side effects reported.
Beyond narcolepsy, researchers are investigating the potential of orexin-boosting medications for other conditions. Because orexin is also involved in attention, reward processing, and motivation, these drugs may eventually be used to treat attention deficit hyperactivity disorder (ADHD), sleep apnea, depression, and addiction. The development of oveporexton represents the first drug in a new category of orexin receptor-2 agonists, with more expected in the coming years.
Professor Guy Leschziner, a neurologist specializing in sleep medicine, described a drug that stimulates or replaces orexin as the long-sought "holy grail" of narcolepsy treatment. He noted that trial data for oveporexton are "extremely encouraging" and expressed anticipation for its availability in the UK. Recent research has also highlighted that narcolepsy can increase the risk of premature death, with sufferers up to 30% more likely to die younger than those without the condition, largely due to sleep disruption-related illnesses such as heart disease and type 2 diabetes.```jsonjson, the Journal of Clinical Sleep Medicine reported in May.